976-71-6
976-71-6 結(jié)構(gòu)式
基本信息
刊利酮
卡利酮
烯睪丙內(nèi)酯
坎利酮-D4
螺內(nèi)酯相關(guān)物質(zhì)A
安體舒通EP雜質(zhì)F
依普利酮CANRENONE雜質(zhì)
6-去氫睪(甾)酮-17α-丙酸-γ-內(nèi)酯
雄甾-4,6-二烯-17β-醇-3-酮-17α-丙酸內(nèi)酯
11614r.p
phanurane
CANRENONE
ALDADIENE
NSC 261713
CANRENONE-D4
Canrenone, >=97%
Canrenone98.5%Min
spirolactonesc14266
物理化學(xué)性質(zhì)
制備方法
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2024/11/11 | XW97671601 | 坎利酮 | 976-71-6 | 1G | 766元 |
| 2024/11/08 | HY-B1438 | 坎利酮 Canrenone | 976-71-6 | 50mg | 500元 |
| 2024/11/08 | HY-B1438 | 坎利酮 Canrenone | 976-71-6 | 10mM * 1mLin DMSO | 550元 |
常見問題列表
|
Human Endogenous Metabolite
|
Canrenone inhibits the production of eortieosterone, 18-hydroxydesoxyeortieosterone, 18-hydroxycorticosterone and aldosterone in a dose-dependent manner. Canrenone dose-dependently reduces platelet-derived growth factor–induced cell proliferation and motility. Canrenone inhibits the activity of the Na + /H + exchanger 1 induced by platelet-derived growth factor.
Canrenone is the principal active metabolite of Spironolactone in the rat only for a limited period. During chronic treatment a difference developed between the effect of Spironolactone and Canrenone on the RAAS indicating a decrease in the anti-mineralocorticoid activity of Canrenone and an increase in the efficacy of Spironolactone.